A specific benefit, not a universal cure
Purified cannabidiol has demonstrated a treatment benefit for certain severe epilepsies. A pivotal 2017 trial in Dravet syndrome tested an oral cannabidiol medicine added to existing antiepileptic treatment. The result was a reduction in convulsive seizure frequency compared with placebo, not a cure for epilepsy or proof that all cannabis products work alike. The distinction is clinically important: CBD was one defined ingredient in a controlled medicinal intervention, used for a particular population with drug-resistant disease.
What the trial compared
The study randomly assigned 120 children and young adults to cannabidiol or placebo alongside their usual treatment. Random allocation creates a comparison between groups receiving different interventions; it is different from collecting stories from people who already chose a product. Here the comparison concerned an additional treatment, so the result cannot be described as evidence that existing antiseizure medicines were unnecessary. It also cannot establish an equivalent effect in people with unrelated conditions or in healthy users.
Seizures decreased, but most did not disappear
Median monthly convulsive seizures changed from 12.4 to 5.9 in the cannabidiol group, compared with 14.9 to 14.1 with placebo. These figures describe a group-level change, not the result for every participant. The reported endpoint was seizure frequency. Calling it a cure would replace that measured outcome with a much larger claim. For a family dealing with frequent seizures, a reduction can still be meaningful without implying complete seizure freedom or removal of every consequence of the underlying syndrome.
The medicine has a safety profile
The FDA identifies potential liver injury with cannabidiol and notes that prescription approval involves balancing benefits and risks for the intended population under medical supervision. A substance being plant-derived does not remove pharmacological effects or monitoring needs. This is compatible with a real therapeutic benefit: effective medicines can also produce adverse effects. The relevant clinical question is whether a specified treatment’s benefits justify its risks for the person and condition being treated.
The European medicine
Epidyolex received EU-wide authorisation on 19 September 2019. It is an add-on treatment for Lennox–Gastaut and Dravet syndromes, used with clobazam from age two. Its tuberous sclerosis complex indication also starts at age two, alongside other epilepsy treatments. This brings cannabidiol into European specialist epilepsy care as a defined prescription medicine.
Sources & further reading
General information, not individual legal or medical advice.